Quisel John D 4

What Happened
John D. Quisel, Chief Executive Officer of Disc Medicine, was granted equity awards on February 10, 2026: 55,200 restricted stock units (RSUs) and an 82,800-share derivative award (option-based). Both grants show a $0.00 acquisition price (typical for compensation grants), so there was no cash paid at the time of grant. Total awards sum to 138,000 shares subject to future vesting.

Key Details

• Transaction date: 2026-02-10; Form 4 filed 2026-02-11 (timely).
• Award amounts: 55,200 RSUs (reported as A) and 82,800 derivative award (reported as A, derivative).
• Price: $0.00 for both awards (compensation grants, not open-market purchases).
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Footnotes:
  • F1 (55,200 RSUs): Each RSU converts to one share; vests in four annual 25% installments beginning February 15, 2027, subject to continued service.
  • F2 (82,800 derivative): The shares underlying this option vest in 48 equal monthly installments beginning March 10, 2026, subject to continued service.
• No immediate sale or exercise reported—these are forward-looking compensation awards.

Context
RSUs and option grants are common forms of executive compensation and do not represent an immediate purchase or sale of stock; value is realized only if and when the awards vest (and, for options, are exercised). Because these awards vest over multi-year schedules and were granted at $0, they are routine retention/incentive grants rather than a direct market signal like an insider buy or sale.